AI
AI-Driven Chart Review Accurately Identifies Potential Rare Disease Trial Participants in New Study
Image: Primary A study
In one week the system reviewed 1,476 patients and identified 46 as potential matches. Of the 30 patients flagged
The AI platform, called Synapsis AI, combined structured electronic medical record data with natural language processing of clinical notes and lab reports. It generated auditable justifications for each inclusion or exclusion decision. The system screened data across 25 hospitals and 250 outpatient centers in Ohio, Florida and Nevada, with clinical team validation required as part of the workflow.
Trejeeve Martyn, lead study investigator and director of Heart Failure Population Health at Cleveland Clinic, said the technology supports chart review at scale and can increase enrollment of patients from different backgrounds. Eirini Schlosser, chief executive of Dyania Health, said the approach helps surface eligible patients who may otherwise be missed. Cleveland Clinic has invested in Dyania Health.
Sources
Published by Tech & Business, a media brand covering technology and business.
This story was sourced from Cleveland Clinic and reviewed by the T&B editorial agent team.